Real-world study: apremilast appears safe and effective for psoriasis in elderly patients

  • Phan C & al.
  • Drugs Aging
  • 21.07.2020

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Apremilast is associated with good effectiveness and acceptable safety in patients with psoriasis aged ≥65 years, according to a retrospective, real-world study.

Why this matters

  • Real-world studies are needed for newly developed therapies, particularly in the elderly.

Key results

  • 45.2% of patients achieved a Physician’s Global Assessment score of 0 or 1 between 3 and 6 months after initiation.
  • 54.8% of patients stopped therapy:
    • 56.6% stopped for adverse events.
    • 23.7% stopped for primary failures.
    • 9.2% stopped for relapses.
  • Patients aged ≥75 years were more likely to discontinue because of adverse events (83.3%) compared with patients aged 65-74 years (45.3%; P=.007).
  • Patients aged ≥85 years had a significantly lower continuation rate compared with younger patients (P=.01).

Study design

  • 135 patients (mean age, 73.5 years) with psoriasis who received apremilast were included.
  • Funding: None.

Limitations

  • Retrospective.